Asparagus Capsule Consumption and Blood Sugar and Lipids and Oxidative Stress

Effects of Asparagus Capsule Consumption on Blood Sugar and Lipids and Oxidative Stress in Overweight and Obese Participants

Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.

Study Overview

• Status: Completed
• Conditions: Asparagus Capsule Consumption
• Intervention / Treatment: Dietary supplement: Asparagus capsule; Other: Placebo capsule

Detailed Description

The study design was cross-sectional. Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels. Analysis of covariance was used to analyze parameters between groups and paired t-test was used to analyze parameters intra-group.

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 2

Contacts and Locations

Study Locations

• Thailand
  • ChonBuri
    • Mueang, ChonBuri, Thailand, 20131
      • Faculty of Allied Health Sciences, Burapha University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Man or woman, aged between 18 to 59 years
• Body mass index more than 23 (Asian criteria)
• No history of hypertension, diabetes, cardiovascular disease, respiratory disease, endocrine disease, neuromuscular disease, musculoskeletal disease, liver disease, renal disease, immune disease, infectious disease, or cancer
• No regular intake of dietary supplements, i.e., vitamins, antioxidants
• No regular smokers or alcohol drinkers (>2 times per week)
• Not sportman or regular exerciser (>2 times per week or >150 min per week)
• No food allergy, especially shoot

Exclusion Criteria:

- Current signs or symptoms of infection, i.e., fever, hyperpnea, dyspnea, and palpitations.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Asparagus capsule; Participants were randomized to receive an arm. In this arm, participants received asparagus capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.	Dietary supplement: Asparagus capsule; Asparagus capsule is categorized as dietary supplement.
Placebo Comparator: Placebo capsule; Participants were randomized to receive an arm. In this arm, participants received placebo capsule and were asked to consume at 40 mg/kg (1-2 capsule) within 15-30 min after breakfast. Consumption was taken at participants' dwelling.	Other: Placebo capsule; Placebo capsule is categorized as other.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Level of body fat	Level of body fat was measured in percentage unit	Day 0 and end of 12 weeks
Level of fat mass	Level of fat mass was measured in kilogram unit	Day 0 and end of 12 weeks
Level of fat distribution	Level of fat distribution was measured by ratio of waist (centimeter) to hip (centimeter)	Day 0 and end of 12 weeks
Concentration of blood glucose	Concentration of blood glucose was measured in serum in mmol/L unit	Day 0 and end of 12 weeks
Concentration of blood insulin	Concentration of blood insulin was measured in serum in uU/mL (microunit/milliliter) unit	Day 0 and end of 12 weeks
Concentrations of blood lipids	Concentrations of total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were measured in serum in mg/dL unit	Day 0 and end of 12 weeks
Concentration of blood malondialdehyde	Concentration of blood malondialdehyde was measured in plasma in uM (micromolar) unit	Day 0 and end of 12 weeks
Concentration of blood protein carbonyl	Concentration of blood protein carbonyl was measured in plasma in nmol/mg protein unit	Day 0 and end of 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Concentrations of blood glucose from oral glucose tolerance test	Concentrations of blood glucose were measured before and after glucose consumption at 75 g/100 ml in mg/dL unit	At 0 minute before glucose consumption and at 30, 60, 90, 120 minutes after glucose consumption

Collaborators and Investigators

• Sponsor: Burapha University
• Investigators: Principal Investigator: Piyapong Prasertsri, Ph.D., Burapha University

Study record dates

Study Major Dates

• Study Start (Actual): December 20, 2022
• Primary Completion (Actual): September 14, 2023
• Study Completion (Actual): September 14, 2023

Study Registration Dates

• First Submitted: December 21, 2023
• First Submitted That Met QC Criteria: January 5, 2024
• First Posted (Actual): January 8, 2024

Study Record Updates

• Last Update Posted (Actual): January 12, 2024
• Last Update Submitted That Met QC Criteria: January 10, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: IRB3-115/2565

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is no plan to make individual participant data available to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No